中国医药(600056.SH)：克拉霉素片药品通过仿制药一致性评价

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the supplemental application of Clarithromycin Tablets, which passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved drug, Clarithromycin, is indicated for the treatment of infections caused by sensitive pathogenic bacteria, including lower respiratory tract infections, upper respiratory tract infections, and skin and soft tissue infections [1]